Facilitating the research of numerous nationally and internationally recognized scientists, in over sixty labs across British Columbia, to improve cancer care.

BC Cancer Research strives to improve the lives of patients through the integration of basic biomedical research, genomics, clinical trials, health services research, cancer surveillance, population health, and the development of innovative new technology, programs, and interventions. Organized through departments and programs with various themes, BC Cancer supports groundbreaking cancer research and personalized care approaches through world-class facilities and platforms including genomics, bioinformatics, imaging, drug development and tissue banking.

Our Research

The success of BC Cancer is driven by the people and their passion to reduce the impact of cancer on people and society. Our 2022 Research Report showcases how BC Cancer continues to be internationally recognized for our excellence in cancer research and its integrated model of cancer planning and care. 

Read the 2022 BC Cancer Research Report

News & Events

Fumiya Inaba receives CIHR Canada Graduate Scholarships - Master's Award

Congratulations to Fumiya Inaba (Integrative Oncology), for receiving a Canada Graduate Scholarships - Master's Award (CGS-M) from the Canadian Institutes of Health Research (CIHR).

The award is tied to a project titled, "Deep Learning Nuclei Segmentation to Predict Risk Groups in Prostate Cancer.”

The CIHR CGS-M awards provide special recognition and financial support to students who are pursuing a Master's degree in a health-related field in Canada, and are expected to have an exceptionally high potential for future research achievement and productivity.

Research Recovery Resources

BC Cancer Research is taking a gradual and careful approach to re-opening research activities to protect our staff, patients and communities.

Access our COVID-19 recovery resources.

Our Strategic Plan

Our Strategic Plan outlines our direction to strengthen our research capabilities and collaboration with departments and partners to improve our ability to generate knowledge, enhance the impact of our research, and support innovation in clinical care.  

Read the BC Cancer Research Strategic Plan.


ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis.

Cancer cell, 2024
Barisic, Darko, Chin, Christopher R, Meydan, Cem, Teater, Matt, Tsialta, Ioanna, Mlynarczyk, Coraline, Chadburn, Amy, Wang, Xuehai, Sarkozy, Margot, Xia, Min, Carson, Sandra E, Raggiri, Santo, Debek, Sonia, Pelzer, Benedikt, Durmaz, Ceyda, Deng, Qing, Lakra, Priya, Rivas, Martin, Steidl, Christian, Scott, David W, Weng, Andrew P, Mason, Christopher E, Green, Michael R, Melnick, Ari

Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22.

Molecular therapy. Oncology, 2024
McComb, Scott, Arbabi-Ghahroudi, Mehdi, Hay, Kevin A, Keller, Brian A, Faulkes, Sharlene, Rutherford, Michael, Nguyen, Tina, Shepherd, Alex, Wu, Cunle, Marcil, Anne, Aubry, Annie, Hussack, Greg, Pinto, Devanand M, Ryan, Shannon, Raphael, Shalini, van Faassen, Henk, Zafer, Ahmed, Zhu, Qin, Maclean, Susanne, Chattopadhyay, Anindita, Gurnani, Komal, Gilbert, Rénald, Gadoury, Christine, Iqbal, Umar, Fatehi, Dorothy, Jezierski, Anna, Huang, Jez, Pon, Robert A, Sigrist, Mhairi, Holt, Robert A, Nelson, Brad H, Atkins, Harold, Kekre, Natasha, Yung, Eric, Webb, John, Nielsen, Julie S, Weeratna, Risini D
Back to top